磁共振成像在预测三阴性乳腺癌新辅助化疗后的病理反应中的应用 - Suppr

Suppr

超能文献

Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy.

作者信息

Chen Jeon-Hor, Mehta Rita S, Carpenter Philip M, Nalcioglu Orhan, Su Min-Ying

出版信息

J Clin Oncol. 2007 Dec 10;25(35):5667-9. doi: 10.1200/JCO.2007.14.6134.

DOI:10.1200/JCO.2007.14.6134

PMID:18065744

Abstract

摘要

相似文献

Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy.磁共振成像在预测三阴性乳腺癌新辅助化疗后的病理反应中的应用

J Clin Oncol. 2007 Dec 10;25(35):5667-9. doi: 10.1200/JCO.2007.14.6134.

Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.在接受新辅助化疗且有或无序贯曲妥珠单抗治疗的局部晚期乳腺癌患者中，使用动态对比增强磁共振成像预测淋巴结状态。

Arch Surg. 2007 Sep;142(9):855-61; discussion 860-1. doi: 10.1001/archsurg.142.9.855.

[Value of dynamic contrast-enhanced MRI in assessment of early response to neoadjuvant chemotherapy in breast cancer].动态对比增强磁共振成像在评估乳腺癌新辅助化疗早期反应中的价值

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):539-43.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.新辅助化疗加曲妥珠单抗治疗后病理完全缓解可预测人表皮生长因子受体 2 过表达乳腺癌的良好生存：AGO 和 GBG 研究组的 TECHNO 试验结果。

J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25.

Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.为何辅助性曲妥珠单抗能使高危HER-2阳性乳腺癌女性患者获得更好的治疗结果。

Breast J. 2006 Sep-Oct;12(5):497-8. doi: 10.1111/j.1075-122X.2006.00314.x.

[Value of diffusion weighted imaging (DWI) in evaluating early response to neoadjuvant chemotherapy in locally advanced breast cancer].[扩散加权成像（DWI）在评估局部晚期乳腺癌新辅助化疗早期疗效中的价值]

Zhonghua Zhong Liu Za Zhi. 2010 May;32(5):377-81.

Case records of the Massachusetts General Hospital. Case 16-2012. A 32-year-old woman with HER2-positive breast cancer.马萨诸塞州总医院病例记录。病例16 - 2012。一名32岁的HER2阳性乳腺癌女性患者。

N Engl J Med. 2012 May 24;366(21):2018-26. doi: 10.1056/NEJMcpc1111576.

Herceptin (trastuzumab): adjuvant and neoadjuvant trials.赫赛汀（曲妥珠单抗）：辅助治疗和新辅助治疗试验。

Isr Med Assoc J. 2006 Jun;8(6):416-21.

[Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].含吡柔比星方案作为原发性乳腺癌新辅助及辅助化疗的疗效分析

Zhonghua Zhong Liu Za Zhi. 2012 Feb;34(2):143-6. doi: 10.3760/cma.j.issn.0253-3766.2012.02.014.

Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].曲妥珠单抗在 HER2 阳性老年乳腺癌患者中作为术后辅助治疗的疗效评估：一项随机对照试验 [RESPECT (N-SAS BC07)]。

Jpn J Clin Oncol. 2011 May;41(5):709-12. doi: 10.1093/jjco/hyr011. Epub 2011 Feb 24.

引用本文的文献

Triple-Negative Papillary Carcinoma of the Breast: A Case Report.乳腺三阴性乳头状癌：一例报告

Cureus. 2024 Sep 9;16(9):e69020. doi: 10.7759/cureus.69020. eCollection 2024 Sep.

Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology.新辅助化疗后 MRI 诊断的残余肿瘤大小的影响因素与病理学的比较。

J Surg Oncol. 2014 Feb;109(2):158-67. doi: 10.1002/jso.23470. Epub 2013 Oct 28.

Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy.磁共振成像在接受新辅助化疗的乳腺癌患者管理中的临床应用。

Biomed Res Int. 2013;2013:348167. doi: 10.1155/2013/348167. Epub 2013 Jun 5.

Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.磁共振成像评估曲妥珠单抗阴性乳腺癌新辅助化疗患者肿瘤反应的诊断性能与分子生物标志物谱相关。

Clin Breast Cancer. 2012 Apr;12(2):110-8. doi: 10.1016/j.clbc.2012.01.009.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验